Advanced Colon Cancer: Antiprogressive Immunotherapy Using an Autologous Hemoderivative

Abstract

The autologous hemoderivative tested is antigenically polyvalent and promotes a polytargeted immune response associated with a tumor antiprogressive effect, consequently, acting as an autologous hemoderivative cancer vaccine.

Advanced breast cancer: anti-progressive immunotherapy using a thermostable autologous hemoderivative

“…Samples obtained before and after treatment (AHD and control) are shown. After AHD treatment the results reproduced the histopathology previously reported in AHD-treated and non-progressors: tumor stromal fibrosis with lymphocyte infiltration and a decrease in tumor cells and vascularity [1,3,6]. The histochemistry of the infiltrating lymphocytes showed a high predominance of CD8+ and CD20+ cells (B cells), with minimal presence of CD4+ cells.…”

“…As it has been previously reported [1][2][3]6], the toxicity of the AHD procedure was negligible and no clinical autoimmunity or immunosuppressive phenomena were observed under the specific conditions of this study.…”

“…After 4 weeks of treatment (AHD or Control), all patients included in the study continued to receive only symptomatic treatment. According to previous reports, the maximal delay and the recovery of tumor growth in the observed AHD effect could be shown during an 8-month follow-up period [3,6]. Therefore, the clinical parameters were assessed monthly for 8 months (primary endpoint).…”

“…The patients included had to have undergone the last cycle of chemotherapy more than 1 month earlier. The study was conducted in patients admitted to medical centers that submitted Months: mean (range) 7.3 (4-9) 6.8 (3)(4)(5)(6)(7)(8) medical data to the Cooperative Trials Center (CTC) of PharmaBlood, R&D Department, Florida, USA (PharmaBlood is a non-pharmaceutical concern company supporting scientific research in medical procedures using hemoderivatives). Written informed consent was obtained from all patients included in the study.…”

“…These findings are compatible with the hypothesis that, within the context of this procedure, AHD elicits an immune response that directly or indirectly modulates the components of the tumor stroma, making the environment less favorable for the survival, proliferation, and migration of malignant cells. These facts were recently confirmed in a more homogeneous patient population with advanced primary colon cancer [6]. In order to gain further insight regarding the anti-tumor effect of this procedure and the proposed immunologic mechanism of action, we designed a prospective randomized clinical trial in patients with advanced breast cancer.…”